Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
This study assessed the spectrum of activity of torezolid (TR-700), the active moiety of torezolid phosphate (TR-701), and proposes tentative MIC and disk diffusion breakpoints as well as quality control ranges. The in vitro susceptibilities of 1,096 bacterial isolates, representing 23 different species or phenotypic groups, were determined for torezolid, linezolid, cefotaxime, and levofloxacin using Clinical and Laboratory Standards Institute (CLSI) broth microdilution MICs, minimum bactericidal concentrations (MBCs), agar dilution, and disk diffusion testing methods. Torezolid was very active against the majority of Gram-positive strains, including methicillin-susceptible and -resistant Staphylococcus aureus (MIC(50) = 0.25 microg/ml, MIC(90) <or= 0.5 microg/ml), coagulase-negative staphylococci (CNS; MIC(50) = 0.25 microg/ml, MIC(90) <or= 0.5 microg/ml), enterococci (MIC(50) and MIC(90) <or= 0.5 microg/ml), and streptococci (MIC(50) and MIC(90) <or= 0.25 microg/ml). Based upon MIC(90)s, torezolid was 4-fold more active than linezolid against S. aureus, coagulase-negative staphylococci, and the enterococci and 8-fold more active than linezolid against the streptococci. With the use of tentative MIC breakpoints of <or=2 microg/ml for susceptibility, torezolid disk diffusion zone diameter breakpoints are proposed using a 20-microg disk. In addition, MIC quality control ranges of torezolid were determined for three CLSI-recognized standard ATCC reference strains.
The Clinical Microbiology Institute, Wilsonville, OR 97070, USA. SBrown@clinmicroinst.com
Steven D
SD
Brown
Maria M
MM
Traczewski
D052978:Disk Diffusion Antimicrobial Tests / Q000592:standards*; D024881:Drug Resistance, Bacterial; D056569:Enterococcaceae / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D049691:History, Medieval; D066298:In Vitro Techniques; D007201:Indicator Dilution Techniques / Q000592:standards; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008828:Microbiological Techniques / Q000592:standards; D010755:Organophosphates / Q000737:chemistry / Q000494:pharmacology*; D010080:Oxazoles / Q000737:chemistry / Q000494:pharmacology*; D023303:Oxazolidinones / Q000737:chemistry / Q000494:pharmacology*; D011786:Quality Control; D013291:Streptococcus / Q000187:drug effects; D013777:Tetrazoles / Q000737:chemistry / Q000494:pharmacology*
D010755:Organophosphates; D010080:Oxazoles; D023303:Oxazolidinones; D013777:Tetrazoles; C546016:tedizolid; C515040:tedizolid phosphate